Cost of Blood Cancer Immunotherapy in India — Three Price Tiers, Not One Number

No. Most people treated for a blood cancer in India never receive immunotherapy. Chemotherapy, steroids, targeted tablets and radiation still do most of the work, and for some the next step is a stem cell transplant. Antibody therapy is standard in defined lymphoma and myeloma regimens. Checkpoint inhibitors and cell therapy apply to far smaller groups.

• “Blood cancer” is not one disease, and it does not have one price — the term covers lymphomas, leukaemias and myeloma, and each is treated along a different pathway. What applies in Hodgkin lymphoma does not automatically apply in non-Hodgkin lymphoma, in leukaemia or in multiple myeloma.
• Antibody therapy is the oldest tier, and the most widely used — monoclonal antibodies have been part of standard lymphoma and myeloma regimens for years, usually given alongside chemotherapy rather than instead of it. Antibody therapy for blood cancers explains why families are often already receiving immunotherapy without the word being used.
• Checkpoint inhibitors have a narrow, defined place here — unlike in lung or skin cancer, they are considered mainly in selected relapsed or refractory settings, under current NCCN and ESMO guidance, and not as a first treatment for most people. If one has been proposed to you, ask which line of treatment it is being used in and why.
• Cell therapy sits outside what CION provides — CION does not provide CAR-T or cell therapy. It is offered at a small number of designated accredited centres, for a defined group of patients whose disease has come back or has not responded. Our role is eligibility review, referral and orientation for the family. What CAR-T is reported to cost in India sets out that pathway.
• Stem cell transplant is a designated-centre pathway too — it is referred to a designated transplant centre rather than carried out here, and its costs sit on a separate ladder from the infusion treatments described on this page. How immunotherapy and transplant fit together covers the sequencing question families ask most.
• Fitness, organ function and immune history are weighed honestly — an active autoimmune condition, an earlier organ transplant, ongoing high-dose steroids or a very low blood count can make a given tier unsuitable regardless of the diagnosis on the report.

It depends on the tier. As of August 2026, one dose of a biosimilar antibody runs roughly ₹25,000 to ₹60,000, and an imported reference antibody roughly ₹70,000 to ₹1,50,000. A checkpoint inhibitor cycle runs roughly ₹50,000 to ₹4,50,000, depending on the product. Cell therapy is not billed per cycle at all. Indicative only.

Why the first cycle usually costs more than the ones after it

Two reasons, and both are normal. The baseline tests are loaded in front. And the first antibody dose is given slowly, with longer observation, because infusion reactions are commonest on day one.

Expect baseline blood counts, liver, kidney and thyroid function, hepatitis B and C screening, and a staging scan before treatment begins — a one-time block of roughly ₹15,000 to ₹40,000, indicative as of August 2026, and more if a fresh biopsy is needed. The first infusion then takes longer chair time, and occasionally an overnight stay is planned for it; what happens during a first-dose infusion reaction explains why that extra time is protective rather than a padded bill. Immunotherapy is administered as day care at CION centres, so a routine cycle carries no inpatient bed charge — if a quote includes one, ask what it is for. Response-assessment PET-CT is coordinated at partner imaging centres rather than owned by CION, and is billed by the imaging centre directly. How to compare two quotes line by line is the check that moves the number most.

Three different classes of treatment, three different brackets. Antibody therapy is billed per dose and measured in lakhs across a course. Checkpoint inhibitor treatment is billed per cycle over months and runs into tens of lakhs. CAR-T is a one-time cell product, reported from tens of lakhs to several crore. Indicative, as of August 2026.

One caution about the word itself. Families often use “immunotherapy” for all three tiers and then compare a figure quoted for one against a figure heard for another. They are not comparable. Before you react to any number, establish which tier it belongs to, whether it is a per-dose, per-cycle or one-time figure, and whether it includes administration and monitoring. Bispecific antibodies and antibody-drug conjugates are two newer formats that families increasingly meet in relapsed blood cancer, and both sit above the older antibody tier on price.

There is no single total, because the number of doses is set by the regimen and by how the disease responds. As of August 2026, a six-dose antibody course is roughly ₹1,50,000 to ₹9,00,000 for the drug alone. Six months of checkpoint treatment runs into tens of lakhs. Indicative only.

Add day care and pre-cycle bloods for every cycle on the first seven rows, and a response scan at the points your oncologist sets. For the cell therapy row, add eligibility workup, cell collection, preparatory chemotherapy and two to four weeks of hospital and near-hospital monitoring, which together commonly add several lakh rupees more. All indicative, as of August 2026. For the national picture across all cancers see what a full course actually comes to in India, and the costs nobody budgets for covers travel, attendant stay and lost workdays — rarely small for a family travelling into Hyderabad, and larger again where treatment means weeks beside a transplant or cell-therapy centre.

Government schemes work to fixed package ceilings, and high-cost immunotherapy commonly sits above them, so cover is often partial. Private policies usually pay for day-care infusion, subject to sub-limits and pre-authorisation. Biosimilar substitution, manufacturer programmes and tax relief cover parts of the rest. None of this is a promise of cover.

• Choosing a biosimilar product — usually the single largest reduction available on an antibody bill. It is a conversation for your oncologist, not a decision to take alone. How much biosimilars actually save.
• Aarogyasri, in Telangana and Andhra Pradesh — chemotherapy packages for blood cancers are well established, and high-cost immunotherapy sits in a different bracket altogether. What the scheme funds and what it does not explains how to ask for the current ceiling in writing rather than over a counter.
• Ayushman Bharat PM-JAY — the same package-ceiling logic applies nationally. Ayushman Bharat and immunotherapy coverage.
• CGHS, ECHS and ESI — approved rate lists plus prior approval. Start the paperwork early.
• Private health insurance — day-care infusion is payable under most modern policies, but sub-limits, waiting periods, pre-existing-disease clauses and pre-authorisation rules decide what you actually receive. A long course can exhaust a sum insured well before treatment ends, which matters more in blood cancer than almost anywhere else. Where immunotherapy claims actually fail.
• Manufacturer patient-assistance programmes — several run assistance or dose-support schemes in India. Eligibility varies, documentation takes time, and applications usually have to be made before the first dose. How they work and how to apply.
• Section 80DDB tax relief — a deduction on documented treatment expenditure, claimed with the right certificate. What you can actually claim.
• Crowdfunding — used widely and unevenly, and more common in cell-therapy and transplant families than anywhere else in oncology. What actually works, and what does not.

Start with the page for your own disease, because the tier that applies to you decides the bracket. Then read what the treatment leaves behind, because the costs after the last infusion are the ones most families are never warned about.

• Immunotherapy for Multiple Myeloma — where antibody therapy is now part of standard regimens, and how that changes the shape of the bill compared with lymphoma.
• Immunotherapy for Leukaemia — a different pathway again, and the disease group where cell therapy questions come up most often in younger patients.
• Low Immunoglobulins and Infection Risk After Blood Cancer Immunotherapy — the recurring cost that arrives after treatment finishes, and the one to build into a budget from the start.
• Immunotherapy at CION Cancer Clinics — how eligibility review, day-care treatment, monitoring, referral for transplant or cell therapy and cost counselling fit together as one pathway.

A Number Your Family Can Actually Plan Against

We put the eligibility answer and the indicative estimate in writing, dated, including the lines most quotes leave out.